Merlin Nexus

Merlin Nexus is a private equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include Zymeworks, Adaptimmune, Stem Cell Therapeutics, Sunesis Pharmaceuticals, MicrometMicromet, and Xencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.

Merlin Nexus is a private equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include Zymeworks, Adaptimmune, Stem Cell Therapeutics, Sunesis PharmaceuticalsSunesis Pharmaceuticals, Micromet, and Xencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.

Merlin Nexus is a private equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United StatesUnited States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include Zymeworks, Adaptimmune, Stem Cell Therapeutics, Sunesis Pharmaceuticals, Micromet, and Xencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.

Merlin Nexus is a private equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include Zymeworks, Adaptimmune, Stem Cell Therapeutics, Sunesis Pharmaceuticals, Micromet, and XencorXencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.

Merlin Nexus is a private equity firmprivate equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include Zymeworks, Adaptimmune, Stem Cell Therapeutics, Sunesis Pharmaceuticals, Micromet, and Xencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.

Merlin Nexus is a private equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include ZymeworksZymeworks, Adaptimmune, Stem Cell Therapeutics, Sunesis Pharmaceuticals, Micromet, and Xencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.

Merlin Nexus is a private equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include Zymeworks, AdaptimmuneAdaptimmune, Stem Cell Therapeutics, Sunesis Pharmaceuticals, Micromet, and Xencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.

Merlin Nexus is a private equity firm based in New York that is focused on investing in the life sciences industry. Founded 2001 in New York, United States, this company invests in Series A, post-IPO equity and venture rounds. Its portfolio companies include Zymeworks, Adaptimmune, Stem Cell Therapeutics, Sunesis Pharmaceuticals, Micromet, and Xencor. As of February 2020, Merlin Nexus has made six investments. Their most recent investment was on Jan 8, 2016, when Zymeworks raised $61.5M. Merlin Nexus has had six exits, the most notable of which include Adaptimmune, Zymeworks, and Xencor.